Sorrento Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018
ASSETS
Current assets:
Cash and cash equivalents
Marketable investments
Restricted cash
Accounts receivables, net
Inventory
Income tax receivable
Prepaid expenses and other
Prepaid expenses
Other current assets
Total current assets

Property and equipment, net
Operating lease right-of-use assets
Intangibles, net
Goodwill
Cost method investments
Restricted cash
Equity investments
Other assets, net
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable
Accrued payroll and related benefits
Accrued expenses and other current liabilities
Accrued legal settlements
Current portion of deferred revenue
Current portion of deferred rent
Current portion of derivative liabilities
Current portion of operating lease liabilities
Current portion of contingent consideration
Acquisition consideration
Income tax payable
Current portion of debt
Total current liabilities

Long-term debt, net of discount
Deferred tax liabilities, net
Deferred revenue
Derivative liabilities
Operating lease liabilities
Deferred rent and other
Contingent consideration
Other long-term liabilities
Total liabilities not subject to compromise
Liabilities subject to compromise
Total liabilities
Equity (Deficit):
Sorrento Therapeutics, Inc. equity (deficit)
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding
Common stock, $0.0001 par value 750,000,000 shares authorized and 551,281,154 and 522,817,137 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Treasury stock, 7,568,182 shares at cost at June 30, 2023, and December 31, 2022
Total Sorrento Therapeutics, Inc. stockholders deficit

Noncontrolling interests
Total deficit
Total liabilities and stockholders' equity (deficit)

Comments